Trial Profile

A Phase 1 Multi-Dose Dose-Escalation Study of Elesclomol Sodium, Administered Once Weekly to Subjects With Solid Tumors.

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elesclomol (Primary)
Indications Solid tumours
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

08 Jun 2010 12-month survival results reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Synta media release.
27 Feb 2009 Status changed from active, no longer recruiting to discontinued. The reasons for the decision to suspend this trial have been reported in a Synta Pharmaceuticals media release.
12 Feb 2009 Dosing has commenced according to a Synta Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com